Duloxetine Capsule, Delayed Release
Product Images NDC 42708-196

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 42708-196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 196 30 Label)

Duloxetine Delayed-Release Capsules USP, 60 mg, box label for 30 capsules by QPharma, Inc. The label includes dosing instructions and storage information to keep at controlled room temperature. It states the product is Rx only and provides the NDC 42708-196-30. Sample labeling not for sale is indicated.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 60 mg delayed release capsules packaging label by QPharma, Inc. The label shows a blister pack containing 10 capsules arranged in two rows of five. The capsules have a two-tone color design with one half white and the other half a red or pink shade. Dosage strength and product name are visible on the packaging.*

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

Chemical structure of Duloxetine hydrochloride, showing its characteristic fused aromatic rings with oxygen and sulfur heteroatoms and an amine group associated with HCl.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

Kaplan-Meier estimator graph depicting the proportion of patients with relapse over time (days) comparing duloxetine treatment versus placebo. The x-axis represents time from randomization to relapse, and the y-axis shows the proportion of patients with relapse. The graph includes two lines: one for placebo and one for duloxetine treatment.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

This Kaplan-Meier curve graphic compares the proportion of patients with relapse over time from randomization in days for Duloxetine versus placebo treatments. The graph shows relapse proportions increasing with time, with the Duloxetine group having a lower relapse rate than the placebo group throughout the study period.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph shows trends of patient improvement across different doses of Duloxetine and placebo.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo groups, illustrating patient response rates across different levels of pain improvement.*

FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating how patient improvement varies with dosage and frequency.*

FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine capsules at different dosages (120 mg twice daily, 60 mg once daily) and placebo. The graph includes four lines representing Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two curves), and placebo, showing the distribution of patient improvement percentages.*

FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines compare Duloxetine 60 mg once daily and placebo, with Duloxetine showing a higher percentage of patients achieving pain relief across all improvement levels.*

FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100. Two lines represent duloxetine (solid) and placebo (dashed), with duloxetine generally showing a higher percentage of patients improved across pain improvement levels.*

FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo based on percent improvement in pain from baseline (BOCF). The x-axis represents percent improvement in pain from baseline in intervals from >0 to 100%, and the y-axis shows the percentage of patients improved. Two lines depict results for placebo and Duloxetine 60 mg, with Duloxetine generally showing higher patient improvement percentages.*

FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The graph shows two lines, one representing placebo and one for Duloxetine, plotted on axes labeled with percent improvement and percentage of patients improved.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

The image shows a blister pack containing 10 delayed-release capsules of Duloxetine 60 mg, a human prescription drug. The capsules are arranged in two rows of five within a white and transparent plastic and foil packaging. The labeler of this product is QPharma, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.